Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;36(9):e24639.
doi: 10.1002/jcla.24639. Epub 2022 Aug 9.

Colistin resistance screening by 3 μg/ml colistin agar in Carbapenemase-producing Enterobacterales

Claudia Soria-Segarra  1   2   3 , Carmen Soria-Segarra  1   4 , Michelle Andrade-Soriano  1 , Tamara Nuñez Quezada  4   5 , Monica C Gestal  6 , Jose Gutierrez-Fernandez  3   7
Affiliations

Colistin resistance screening by 3 μg/ml colistin agar in Carbapenemase-producing Enterobacterales

Claudia Soria-Segarra et al. J Clin Lab Anal. 2022 Sep.

Abstract

Background: In low- and middle-income countries, the use of colistin in therapeutic regimens is common, to treat infections produced for Carbapenemase-producing Enterobacterales (CPE) due to limited access to the recently discovered-approved antibiotics. Furthermore, the technical limitations to perform colistin susceptibility tests make it difficult to assess the suitability of this treatment for each patient, as well as to monitor the rates of resistance. In the present study, we describe the use of agar dilution using a unique colistin concentration of 3 μg/ml to discriminate isolates with colistin resistance in CPE obtained from clinical samples.

Methods: Clinical Laboratory Standards Institute (CLSI) colistin broth microdilution method and dilution agar with a colistin concentration of 3 μg/ml were performed in 168 isolates of CPE obtained from clinical samples in Guayaquil, Ecuador. Broth microdilution was considered our gold standard using CLSI breakpoints as reference (≤2 μg/ml intermediate and ≥4 μg/ml resistant). Categorical agreement was defined as obtaining a reading within the same category with both methodologies.

Results: Isolates obtained from respiratory samples were the most prevalent (26.19%; n = 44). Klebsiella pneumoniae was the predominant specie (94.04%; n = 158). KPC-like carbapenemase was present in all the isolates, and interestingly, colistin resistance was not mediated by MCR-1 production. Categorical agreement between both methods resulted in 97.02%.

Conclusion: We propose the use of dilution agar with a colistin concentration of 3 μg/ml, as a valid method for screening colistin resistance in low- and middle-income countries to monitor resistance and to perform epidemiological studies.

Keywords: Carbapenemase-producing Enterobacterales; broth microdilution; colistin dilution agar; colistin resistance; surveillance.

PubMed Disclaimer

Conflict of interest statement

None to declare.

Figures

FIGURE 1
FIGURE 1
Colistin MICs distribution and interpretation according to CLSI breakpoints.
See this image and copyright information in PMC

References

    1. Fraenkel‐Wandel Y, Raveh‐Brawer D, Wiener‐Well Y, Yinnon AM, Assous MV. Mortality due to blaKPC Klebsiella pneumoniae bacteraemia. J Antimicrob Chemother. 2016;71(4):1083‐1087. - PubMed
    1. Nordmann P, Poirel L. Epidemiology and diagnostics of carbapenem resistance in gram‐negative bacteria. Clin Infect Dis. 2019;69(Suppl 7):S521‐S528. - PMC - PubMed
    1. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem‐hydrolyzing β‐lactamase, KPC‐1, from a carbapenem‐resistant strain of Klebsiella pneumoniae . Antimicrob Agents Chemother. 2001;45(4):1151‐1161. - PMC - PubMed
    1. Peyclit L, Baron SA, Rolain JM. Drug repurposing to fight colistin and carbapenem‐resistant bacteria. Front Cell Infect Microbiol. 2019;9:1‐11. - PMC - PubMed
    1. Doi Y. Treatment options for carbapenem‐resistant gram‐negative bacterial infections. Clin Infect Dis. 2019;69(Suppl 7):S565‐S575. - PMC - PubMed